Presenting Preclinical Data at 2022 International Congress of Parkinson’s Disease and Movement Disorders in Madrid, Spain
Upcoming Presentation on GBA-PD program at First International Symposium on GBA-PD in Jerusalem, Israel
BETHESDA, Md., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today announced that the Company will present at two upcoming medical meetings in September 2022. Details for the presentations are as follows:
|MDS 2022 International Congress of Parkinson’s Disease and Movement Disorders|
|Poster Title:||GT-02287, a brain-penetrant structurally targeted allosteric regulator of glucocerebrosidase shows evidence of pharmacological efficacy in conduritol β-epoxide (CBE) models of Parkinson’s disease|
|Date/time:||Saturday, September 17, 2022 at 1:00 PM CEST|
|Location:||Madrid Marriott Auditorium Hotel & Conference Center|
|Presentation Station: 8|
|Presenter:||Beatriz Calvo-Flores Guzman, Ph.D., Gain Therapeutics|
|Shaare Zedek Medical Center GBA-PD Symposium|
|Session:||Disease-Modifying Strategies: New Concepts and Innovative Clinical Trials|
|Presentation:||Non-inhibitory Chaperones for GBA-PD|
|Date/time:||Thursday, September 22, 2022 at 3:05 PM EEST|
|Presenter:||Manolo Bellotto, Ph.D., Chief Strategy Officer & General Manager, Gain Therapeutics|
The poster presented at the MDS Congress in Madrid will be available on the Science & Technology section of the Company’s website at https://www.gaintherapeutics.com/science-technology/posters.html, following the presentation.
About Gain Therapeutics, Inc.
Gain Therapeutics, Inc. is transforming the drug discovery paradigm with structurally targeted allosteric regulators identified with its proprietary computational discovery platform SEE-Tx®. The ability to identify never-seen-before allosteric targets on proteins involved in diseases across the full spectrum of therapeutic areas provides opportunities for a range of drug-protein interactions, including protein stabilization, protein destabilization, targeted protein degradation, allosteric inhibition and allosteric activation. Gain’s pipeline spans neurodegenerative diseases, lysosomal storage disorders, metabolic diseases and oncology. Gain’s lead program in Parkinson’s disease has been awarded funding support from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and The Silverstein Foundation for Parkinson’s with GBA, as well as from the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 research and Innosuisse. For more information, please visit https://www.gaintherapeutics.com.
Investor & Media Contact: